CellaVision ABCVLLY +12.06%69 PEG Ratio is 2.81 as of Jun. 24, 2026, which is 15% below its 10-year median of 3.32. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 206 Medical Devices & Instruments companies, CellaVision AB ranks worse than 68.45% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for CellaVision AB's PEG Ratio or its related term are showing as below:
CVLLY'
s PEG Ratio Range Over the Past 10 Years
Min: 0.56 Med: 3.32 Max: 9.45
Current: 2.9
During the past 13 years, CellaVision AB's highest PEG Ratio was 9.45. The lowest was 0.56. And the median was 3.32.
CVLLY's PEG Ratio is ranked worse than 68.45% of 206
companies
in the Medical Devices & Instruments industry
Industry Median: 1.95
vs CVLLY: 2.90
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
CellaVision AB (OTCPK:CVLLY) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
CellaVision AB PEG Ratio Related Terms
CellaVision AB PEG Ratio Historical Data
* Premium members only.
The historical data trend for CellaVision AB's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB PEG Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's PEG Ratio distribution charts can be found below:
* The bar in red indicates where CellaVision AB's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
CellaVision AB (CVLLY) has a PEG Ratio of 2.81 as of Jun. 24, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on CellaVision AB and its competitors. This is 15% below median its historical median of 3.32. Over the past decade, CellaVision AB's PEG Ratio has ranged from 0.56 to 9.45. According to the industry distribution chart, CellaVision AB ranks #141 out of 206 companies in the Medical Devices & Instruments industry, placing it in the top 68.4%.
Is CellaVision AB's PEG Ratio too high?
CellaVision AB's current PEG Ratio of 2.81 is 15% below median its 10-year median of 3.32. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 9.45. The Medical Devices & Instruments industry median PEG Ratio is 1.95. CellaVision AB's value of 2.81 is 44.1% above this industry median. Based on the distribution chart, CellaVision AB ranks #141 out of 206 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's PEG Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #141 out of 206 companies for PEG Ratio. This places CellaVision AB in the lower half of its industry. The industry median PEG Ratio is 1.95. CellaVision AB's value of 2.81 is 44.1% above this benchmark. Historically, CellaVision AB's own PEG Ratio has ranged from 0.56 to 9.45 over the past decade. While the company's 10-year median is 3.32 vs. the industry median of 1.95, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Devices & Instruments company?
The median PEG Ratio among Medical Devices & Instruments companies is 1.95, based on 206 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current PEG Ratio of 2.81 is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median PEG Ratio is 1.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current PEG Ratio is 2.81, which is 15% below median its own 10-year median of 3.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current PEG Ratio is 2.81, which is 15% below median its 10-year median of 3.32 and 44.1% above the Medical Devices & Instruments industry median of 1.95. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current PEG Ratio is 2.81 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
PEG Ratio: 2.81 (15% below median its 10-year median of 3.32)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 44.1% above the Medical Devices & Instruments median (#141 of 206)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
